Respiratory Distress Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major respiratory distress syndrome markets are expected to exhibit a CAGR of 4.56% during 2024-2034.
The respiratory distress syndrome market has been comprehensively analyzed in IMARC's new report titled "Respiratory Distress Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Respiratory distress syndrome, also referred to as hyaline membrane disease, is a respiratory condition that primarily affects premature infants. This illness leads to insufficient production of a substance called surfactant in the lungs, which helps to keep the air sacs (alveoli) open and prevents their collapse during exhalation. As a result, infants suffering from the ailment may experience difficulty breathing enough oxygen and expelling carbon dioxide. Various other common symptoms associated with the disease include rapid and shallow breathing, grunting sounds during exhalation, flaring of the nostrils, a bluish discoloration of the skin, retractions, a faster-than-normal heart rate, etc. The diagnosis of respiratory distress syndrome typically involves a combination of medical history, clinical indications, and a physical examination. A chest X-ray is often performed to evaluate the patient's lung structure and look for characteristic signs of the ailment, such as a ground-glass appearance, air bronchograms, and reduced lung expansion. The healthcare provider may further conduct a blood gas analysis to measure the oxygen and carbon dioxide levels in the blood.
The increasing cases of premature births that affect the normal growth of the lung or the production of surfactant in infants are primarily driving the respiratory distress syndrome market. In addition to this, the rising prevalence of maternal smoking, which can trigger an inflammatory response and generate oxidative stress in the developing fetus, is also bolstering the market growth. Moreover, the widespread adoption of continuous positive airway pressure therapy, since it works by opening the air sacs to help in maintaining lung volume and preventing the collapse of alveoli during expiration, is acting as another significant growth-inducing factor. Apart from this, the escalating application of surfactant replacement therapy, which restores the deficient surfactant in the lungs of patients, thereby boosting the oxygenation capacity of the lungs, reducing surface tension, and promoting pulmonary functions, is further creating a positive outlook for the market. Additionally, the emerging popularity of high-frequency oscillatory ventilation techniques over conventional procedures owing to the decreased risk of lung injury associated with high pressures, is expected to drive the respiratory distress syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the respiratory distress syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for respiratory distress syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the respiratory distress syndrome market in any manner.
Recent Developments:
In October 2023, GEn1E Lifesciences Inc. was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of the company's new therapy for acute respiratory distress syndrome. This will help to accelerate the development of GEn1E's new, first-of-its-kind p38a: MK2 Signal Modifier treatment for acute respiratory distress syndrome.
Key Highlights:
Respiratory distress syndrome is typically seen in preterm newborns due to surfactant deficit (93% of infants under 28 weeks).
Approximately 10% of late preterm newborns and 1% of term neonates may have respiratory distress syndrome.
The American Lung Association reports that around 190,000 Americans are diagnosed with acute respiratory distress syndrome each year.
The mortality rate of respiratory distress syndrome remains high, over 40 percent.
The most common causes of respiratory distress in neonates were transient tachypnea of the newborn (TTN) (22.0%), meconium aspiration syndrome (MAS) (16.90%), respiratory distress syndrome (RDS) (20%), sepsis (14%), and perinatal asphyxia (12%).
Drugs:
Infasurf (calfactant) is a sterile and non-pyrogenic lung surfactant. Infasurf is specifically suggested to prevent respiratory distress syndrome in preterm newborns at high risk for respiratory distress syndrome, as well as to treat (rescue) premature infants who develop the disease.
GEn-1124 is under development by GEn1E Lifesciences for the treatment of acute respiratory distress syndrome. The drug candidates work by targeting mitogen-activated protein kinase 14 (MAP Kinase p38 Alpha). It is delivered via the intravenous method.
Glenzocimab is a monoclonal antibody fragment that is entirely humanized and targets the human platelet glycoprotein VI (GPVI), which is implicated in thrombus development, growth, and stability.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the respiratory distress syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the respiratory distress syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current respiratory distress syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the respiratory distress syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the respiratory distress syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the respiratory distress syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of respiratory distress syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of respiratory distress syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of respiratory distress syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with respiratory distress syndrome across the seven major markets?
What is the size of the respiratory distress syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of respiratory distress syndrome?
What will be the growth rate of patients across the seven major markets?
Respiratory Distress Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for respiratory distress syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the respiratory distress syndrome market?
What are the key regulatory events related to the respiratory distress syndrome market?
What is the structure of clinical trial landscape by status related to the respiratory distress syndrome market?
What is the structure of clinical trial landscape by phase related to the respiratory distress syndrome market?
What is the structure of clinical trial landscape by route of administration related to the respiratory distress syndrome market?
The respiratory distress syndrome market has been comprehensively analyzed in IMARC's new report titled "Respiratory Distress Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Respiratory distress syndrome, also referred to as hyaline membrane disease, is a respiratory condition that primarily affects premature infants. This illness leads to insufficient production of a substance called surfactant in the lungs, which helps to keep the air sacs (alveoli) open and prevents their collapse during exhalation. As a result, infants suffering from the ailment may experience difficulty breathing enough oxygen and expelling carbon dioxide. Various other common symptoms associated with the disease include rapid and shallow breathing, grunting sounds during exhalation, flaring of the nostrils, a bluish discoloration of the skin, retractions, a faster-than-normal heart rate, etc. The diagnosis of respiratory distress syndrome typically involves a combination of medical history, clinical indications, and a physical examination. A chest X-ray is often performed to evaluate the patient's lung structure and look for characteristic signs of the ailment, such as a ground-glass appearance, air bronchograms, and reduced lung expansion. The healthcare provider may further conduct a blood gas analysis to measure the oxygen and carbon dioxide levels in the blood.
The increasing cases of premature births that affect the normal growth of the lung or the production of surfactant in infants are primarily driving the respiratory distress syndrome market. In addition to this, the rising prevalence of maternal smoking, which can trigger an inflammatory response and generate oxidative stress in the developing fetus, is also bolstering the market growth. Moreover, the widespread adoption of continuous positive airway pressure therapy, since it works by opening the air sacs to help in maintaining lung volume and preventing the collapse of alveoli during expiration, is acting as another significant growth-inducing factor. Apart from this, the escalating application of surfactant replacement therapy, which restores the deficient surfactant in the lungs of patients, thereby boosting the oxygenation capacity of the lungs, reducing surface tension, and promoting pulmonary functions, is further creating a positive outlook for the market. Additionally, the emerging popularity of high-frequency oscillatory ventilation techniques over conventional procedures owing to the decreased risk of lung injury associated with high pressures, is expected to drive the respiratory distress syndrome market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the respiratory distress syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for respiratory distress syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the respiratory distress syndrome market in any manner.
Recent Developments:
In October 2023, GEn1E Lifesciences Inc. was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of the company's new therapy for acute respiratory distress syndrome. This will help to accelerate the development of GEn1E's new, first-of-its-kind p38a: MK2 Signal Modifier treatment for acute respiratory distress syndrome.
Key Highlights:
Respiratory distress syndrome is typically seen in preterm newborns due to surfactant deficit (93% of infants under 28 weeks).
Approximately 10% of late preterm newborns and 1% of term neonates may have respiratory distress syndrome.
The American Lung Association reports that around 190,000 Americans are diagnosed with acute respiratory distress syndrome each year.
The mortality rate of respiratory distress syndrome remains high, over 40 percent.
The most common causes of respiratory distress in neonates were transient tachypnea of the newborn (TTN) (22.0%), meconium aspiration syndrome (MAS) (16.90%), respiratory distress syndrome (RDS) (20%), sepsis (14%), and perinatal asphyxia (12%).
Drugs:
Infasurf (calfactant) is a sterile and non-pyrogenic lung surfactant. Infasurf is specifically suggested to prevent respiratory distress syndrome in preterm newborns at high risk for respiratory distress syndrome, as well as to treat (rescue) premature infants who develop the disease.
GEn-1124 is under development by GEn1E Lifesciences for the treatment of acute respiratory distress syndrome. The drug candidates work by targeting mitogen-activated protein kinase 14 (MAP Kinase p38 Alpha). It is delivered via the intravenous method.
Glenzocimab is a monoclonal antibody fragment that is entirely humanized and targets the human platelet glycoprotein VI (GPVI), which is implicated in thrombus development, growth, and stability.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the respiratory distress syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the respiratory distress syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current respiratory distress syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the respiratory distress syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the respiratory distress syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the respiratory distress syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of respiratory distress syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of respiratory distress syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of respiratory distress syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with respiratory distress syndrome across the seven major markets?
What is the size of the respiratory distress syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of respiratory distress syndrome?
What will be the growth rate of patients across the seven major markets?
Respiratory Distress Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for respiratory distress syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the respiratory distress syndrome market?
What are the key regulatory events related to the respiratory distress syndrome market?
What is the structure of clinical trial landscape by status related to the respiratory distress syndrome market?
What is the structure of clinical trial landscape by phase related to the respiratory distress syndrome market?
What is the structure of clinical trial landscape by route of administration related to the respiratory distress syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RESPIRATORY DISTRESS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RESPIRATORY DISTRESS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RESPIRATORY DISTRESS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 RESPIRATORY DISTRESS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RESPIRATORY DISTRESS SYNDROME - UNMET NEEDS
10 RESPIRATORY DISTRESS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 RESPIRATORY DISTRESS SYNDROME - MARKETED PRODUCTS
11.1 List of Respiratory Distress Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Infasurf (Calfactant) - Ony
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Curosurf (Poractant alfa) - Chiesi/Karolinska Institute
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RESPIRATORY DISTRESS SYNDROME - PIPELINE DRUGS
12.1 List of Respiratory Distress Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 GEn-1124 - GEn1E Lifesciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BAY 1211163 - Bayer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Veru-111 - Veru Healthcare
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Reparixin - Dompe Farmaceutici
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Glenzocimab - Acticor Biotech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RESPIRATORY DISTRESS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RESPIRATORY DISTRESS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RESPIRATORY DISTRESS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Respiratory Distress Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Respiratory Distress Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Respiratory Distress Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Respiratory Distress Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Respiratory Distress Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Respiratory Distress Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Respiratory Distress Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Respiratory Distress Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Respiratory Distress Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Respiratory Distress Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Respiratory Distress Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Respiratory Distress Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Respiratory Distress Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Respiratory Distress Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Respiratory Distress Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Respiratory Distress Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
16 RESPIRATORY DISTRESS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RESPIRATORY DISTRESS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RESPIRATORY DISTRESS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 RESPIRATORY DISTRESS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 RESPIRATORY DISTRESS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 RESPIRATORY DISTRESS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 RESPIRATORY DISTRESS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 RESPIRATORY DISTRESS SYNDROME - UNMET NEEDS
10 RESPIRATORY DISTRESS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 RESPIRATORY DISTRESS SYNDROME - MARKETED PRODUCTS
11.1 List of Respiratory Distress Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Infasurf (Calfactant) - Ony
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Curosurf (Poractant alfa) - Chiesi/Karolinska Institute
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 RESPIRATORY DISTRESS SYNDROME - PIPELINE DRUGS
12.1 List of Respiratory Distress Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 GEn-1124 - GEn1E Lifesciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 BAY 1211163 - Bayer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Veru-111 - Veru Healthcare
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Reparixin - Dompe Farmaceutici
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Glenzocimab - Acticor Biotech
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. RESPIRATORY DISTRESS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. RESPIRATORY DISTRESS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 RESPIRATORY DISTRESS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Respiratory Distress Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Respiratory Distress Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Respiratory Distress Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Respiratory Distress Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Respiratory Distress Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Respiratory Distress Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Respiratory Distress Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Respiratory Distress Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Respiratory Distress Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Respiratory Distress Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Respiratory Distress Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Respiratory Distress Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Respiratory Distress Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Respiratory Distress Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Respiratory Distress Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Respiratory Distress Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Respiratory Distress Syndrome - Access and Reimbursement Overview
16 RESPIRATORY DISTRESS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 RESPIRATORY DISTRESS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 RESPIRATORY DISTRESS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
